Screener
ANI Pharmaceuticals ANIP EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from ANI Pharmaceuticals’s reported figures.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's EBITDA?
- ANI Pharmaceuticals (ANIP) reported EBITDA of $60.1M in Q2 2026.
- How has ANI Pharmaceuticals's EBITDA changed year-over-year?
- ANI Pharmaceuticals's EBITDA increased by 61.7% year-over-year, from $37.17M to $60.1M.
- What is the long-term trend for ANI Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's EBITDA has grown at a 128.3% compound annual growth rate (CAGR), from $7.46M to $202.51M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about ANI Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude